|04/24/14||Zogenix Announces Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International|
|Conference Call Scheduled for 8:30 am ET on Thursday, April 24, 2014
SAN DIEGO, April 24, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced today that it has entered a definitive agreement to sell its SUMAVEL® DosePro® Needle-free Delivery System (sumatriptan injection) migraine therapy business to Endo International plc (Nasdaq:ENDP) for $... |
|04/24/14||A Common Sense Approach to Appropriate Drug Use|
|SAN DIEGO, April 24, 2014 /PRNewswire/ -- We at Zogenix have reviewed the letter to Vermont Governor Peter Shumlin signed by the Center for Lawful Access and Abuse Deterrence (CLAAD), The American Academy of Pain Management and the National Fibromyalgia & Chronic Pain Association, which asks the Governor and health commissioner to participate in a "multi-lateral meeting to develop a more thorough approach" to stemming Vermont's prescription drug abuse epidemic. We agree with and commit our... |
|04/23/14||Zogenix Responds to Governor's Action Singling Out Zohydro™ ER in Massachusetts, Encourages Officials to Consider Patient Needs and Effective Class-Wide Measures|
|SAN DIEGO, April 23, 2014 /PRNewswire/ -- Zogenix will continue to work to ensure patients suffering from severe chronic pain have access to the FDA-approved medications they need in every state nationwide, including Massachusetts. We are once again disappointed that Governor Patrick would issue another immediate restriction without first accepting our offer to discuss the facts and work together to address the needs of patients while combating abuse and addiction.
We fully support appropriat... |
|04/15/14||Zogenix Announces Ruling Preventing the Implementation of Massachusetts Governor's Order that Blocked Access to Zohydro™ ER|
|SAN DIEGO, April 15, 2014 /PRNewswire/ -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order, preventing the implementation of the Commonwealth's ban of Zohydro™ ER on Constitutional grounds. This order will become effective on April 22, 2014.
The court decision today supports the importance of... |